Results 241 to 250 of about 195,829 (332)

(±)VK4-40, a novel dopamine D₃ receptor partial agonist, attenuates cocaine reward and relapse in rodents. [PDF]

Br J Pharmacol, 2020
Jordan CJ, He Y, Bi GH, You ZB, Cao J, Xi ZX, Newman AH.   +6 more
europepmc   +1 more source

Tegaserod, a 5‐HT₄ receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects [PDF]

, 2001
Lukas Degen, Daniel Matzinger, Michael Merz, Silke Appel‐Dingemanse, Stuart Osborne, S. Lüchinger, R. Bertold, Helmut R. Maëcke, Christoph Beglinger   +8 more
openalex   +1 more source

Targeting HDAC and PARP Enhances STING‐Dependent Antitumor Immunity in STING‐Deficient Tumor

Advanced Science, EarlyView.
Dual HDAC and PARP inhibition restores STING signaling, enhances interferon response, and boosts antitumor immunity in STING‐deficient tumors. . Abstract The stimulator of interferon genes (STING)‐mediated innate immune pathway plays an important role in tumor immunosurveillance.
Chengzhou Mao, Weiwen Fan, Jiaqi Liu, Fangzhou Yang, Wenkai Li, Lulu Li, Zhichao Shi, Qinyuan Li, Zigao Yuan, Yuyang Jiang, Bizhu Chu   +10 more
wiley   +1 more source

Personalized Neoantigen Vaccine plus Regorafenib Increases Rgs2⁺CD8⁺ T Cells Infiltration and Reprograms the Tumor Microenvironment in Microsatellite Stable Colorectal Cancer Liver Metastases

Advanced Science, EarlyView.
This study synthesized a personalized neoantigen vaccine (Neo‐CRCVAS) and combined it with regorafenib, termed RegoNeo. This combination therapy significantly enhanced antitumor efficacy and promoted long‐term tumor‐specific immune memory in microsatellite stable colorectal cancer liver metastasis (MSS‐CRLM) models by increasing neoantigen‐specific ...
Hengkai Chen, Bin Chen, Yuanfeng Yang, Shoufeng Li, Huajun Cai, Zhicheng Zhuang, Yong Wu, Yuan Gao, Yupeng Chen, Xing Liu, Guoxian Guan, Jinfu Zhuang   +11 more
wiley   +1 more source

Anti-PTSD Effects of Hypidone Hydrochloride (YL-0919): A Novel Combined Selective 5-HT Reuptake Inhibitor/5-HT_1A Receptor Partial Agonist/5-HT₆ Receptor Full Agonist. [PDF]

Front Pharmacol, 2021
Liu WG, Zhang LM, Yao JQ, Yin YY, Zhang XY, Li YF, Cao JB.   +6 more
europepmc   +1 more source

Novel histamine H₃‐receptor antagonists and partial agonists with a non‐aminergic structure [PDF]

, 2001
Tobias Nickel, U. Bauer, Eberhard Schlicker, M. Kathmann, Manfred Göthert, Astrid Sasse, Holger Stark, Walter Schunack   +7 more
openalex   +1 more source

The Long-Acting D3 Partial Agonist MC-25-41 Attenuates Motivation for Cocaine in Sprague-Dawley Rats. [PDF]

Biomolecules, 2020
Powell GL, Namba MD, Vannan A, Bonadonna JP, Carlson A, Mendoza R, Chen PJ, Luetdke RR, Blass BE, Neisewander JL.   +9 more
europepmc   +1 more source

Buprenorphine in acute pain: a partial agonist or not? [PDF]

British Journal of Anaesthesia, 2019
Rhys S. Holyoak, Christopher Thang, Leigh White, Ruan Vlok, Thomas M Melhuish   +4 more
openaire   +2 more sources

The CC Chemokine Eotaxin (CCL11) Is a Partial Agonist of CC Chemokine Receptor 2b [PDF]

, 2001
Roberta Martinelli, Ian Sabroe, Greg LaRosa, Timothy J. Williams, James E. Pease   +4 more
openalex   +1 more source

SenExo‐cCCT2 Reprograms Senescence Response and Anti‐Tumor Immunity Following FOLFIRINOX Chemotherapy in Pancreatic Ductal Adenocarcinoma

Advanced Science, EarlyView.
This study demonstrates that SenExo‐cCCT2 enables targeted delivery of cCCT2 to pancreatic cancer cells, where it disrupts IPO13‐mediated nuclear translocation of UBC9, impairing SUMOylation‐dependent DNA damage repair and inducing senescence. Senescent tumor cells secrete CXCL10 to recruit CD8⁺ T‐cells while upregulating PD‐L1.
Shuncang Zhu, Yinhao Chen, Hongyi Lin, Jinpeng Lu, Yu Pan, Ge Li, Yongding Wu, Haoxiang Zhang, Xiaoxiao Huang, Yiting Chen, Huangjing Chen, Long Jin, Min Huang, Chengyu Liao, Long Huang, Yifeng Tian, Zuwei Wang, Qiaowei Li, Shi Chen   +18 more
wiley   +1 more source